Novo Nordisk A/s Class B · OMXCOP:NOVO_B
Novo Nordisk A/s Class B — Technical Presentation (September 2025)
5 slides from Novo Nordisk A/s Class B's technical presentation, Sep 15, 2025
Slide 1: Oral Semaglutide 25 mg in Adults with Overweight or Obesity
Synopsis of the original article Oral Semaglutide 25 mg in Adults with Overweight or Obesity Wharton S, et al. N Engl J Med 2025; DOI: 10.1056/NEJMoa2500969 Synopsis created and reviewed by Novo Nordisk © 2025 Novo Nordisk A/S; Further reproduction and distribution is permitted
Slide 2: Introduction
Introduction SCIENCEHUB.NOVONORDISK.COM 25 mg Oral semaglutide 25 mg may provide an alternative treatment option to injectable semaglutide 2.4 mg for persons with overweight or obesity © 2025 Novo Nordisk A/S Further reproduction and distribution is permitted
Slide 3: OASIS 4 trial design
OASIS 4 trial design SCIENCEHUB.NOVONORDISK.COM Trial design Participants with a Once-daily oral semaglutide 25 mg N=307 + lifestyle intervention BMI of ≥30 kg/m2 (or This double-blind, R a BMI of ≥27 kg/m2 randomised, placebo- 2:1 Placebo with ≥1 ORC) without controlled, 71-week study + lifestyle i
Slide 4: Oral semaglutide 25 mg led to superior and clinically meaningful weight loss compared with placebo
Oral semaglutide 25 mg led to superior and clinically meaningful weight loss compared with placebo SCIENCEHUB.NOVONORDISK.COM Estimated change in body weight Participants in the oral semaglutide vs placebo group were from baseline to week 64 significantly more likely to: Oral semaglutide 25 mg Place
Slide 5: Conclusions
Conclusions SCIENCEHUB.NOVONORDISK.COM Once-daily oral semaglutide 25 mg 25 mg resulted in superior mean body weight reduction compared with placebo in participants with overweight or obesity © 2025 Novo Nordisk A/S Further reproduction and distribution is permitted
Novo Nordisk — Technical Presentation (September 2025) on 6ix